1 month Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered. Investor's Business Daily
Incyte stock tumbled Tuesday after the company scrapped one drug and paused enrollment in the study of another.
The post Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered. appeared first on Investor's Business Daily.